StockNews.com began coverage on shares of NantHealth (NASDAQ:NH – Get Rating) in a report published on Wednesday morning. The brokerage issued a hold rating on the stock.
NantHealth Price Performance
NantHealth stock opened at $3.46 on Wednesday. NantHealth has a one year low of $1.57 and a one year high of $15.75. The stock's 50 day moving average is $2.59 and its 200 day moving average is $1.16. The firm has a market cap of $26.68 million, a P/E ratio of -0.45 and a beta of 1.88.
Get
NantHealth alerts:
NantHealth (NASDAQ:NH – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.13) EPS for the quarter. The firm had revenue of $16.63 million during the quarter.
Institutional Investors Weigh In On NantHealth
Several institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new position in NantHealth during the 2nd quarter worth approximately $36,000. Hartline Investment Corp purchased a new position in shares of NantHealth in the second quarter valued at about $65,000. Millennium Management LLC purchased a new position in shares of NantHealth in the second quarter valued at about $110,000. Finally, Atria Wealth Solutions Inc. purchased a new position in shares of NantHealth in the first quarter valued at about $170,000. Institutional investors own 4.50% of the company's stock.
NantHealth Company Profile
(Get Rating)
NantHealth, Inc is an evidence-based, personalized healthcare company, which engages in the provision of treatment for critical diseases such as cancer. The firm empowers treatment decisions, improves patient outcomes, validates treatment options, enables high-quality care, lowers costs, ensures appropriate reimbursement, and streamlines implementation and deployment.
Featured Articles
- Get a free copy of the StockNews.com research report on NantHealth (NH)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com开始对股票进行报道NantHealth(纳斯达克：NH-GET评级)在周三上午发布的一份报告中。该券商对该股发布了持有评级。
NantHealth价格表现
周三，NantHealth的股票开盘报3.46美元。NantHealth的一年低点为1.57美元，一年高位为15.75美元。该股的50日移动均线切入位在2.59美元，200日移动均线切入位在1.16美元。该公司的市值为2668万美元，市盈率为-0.45，贝塔系数为1.88。
到达
NantHealth警报：
NantHealth(纳斯达克：NH-GET评级)最近一次发布季度收益数据是在11月3日星期四。该公司公布了该季度每股收益(0.13美元)。该公司本季度的收入为1663万美元。
机构投资者看好NantHealth
几家机构投资者最近买卖了该股的股票。高盛股份有限公司在第二季度购买了价值约36,000美元的南洋健康新头寸。Hartline Investment Corp在第二季度购买了NantHealth的新头寸，价值约65,000美元。Millennium Management LLC在第二季度购买了NantHealth的新头寸，价值约11万美元。最后，Atria Wealth Solutions Inc.在第一季度购买了NantHealth的新头寸，价值约17万美元。机构投资者持有该公司4.50%的股份。
NantHealth公司简介
(获取评级)
NantHealth，Inc.是一家以证据为基础的个性化保健公司，致力于为癌症等危重疾病提供治疗。该公司支持治疗决策，改善患者结局，验证治疗选项，实现高质量护理，降低成本，确保适当的报销，并简化实施和部署。
专题文章
- 免费获取StockNews.com关于NantHealth(NH)的研究报告
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet盈利节节攀升，增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
- 内部人士和机构收购金刚狼全球
接受《NantHealth Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对NantHealth和相关公司的最新新闻和分析师评级的每日简要摘要。
